The enduring impact that imatinib (Gleevec, Novartis Pharmaceuticals) has made on the treatment of chronic myelogenous leukemia (CML), as well as on the whole field of oncology, has been highlighted ...

June 6, 2011 (Chicago, Illinois) — Extended adjuvant treatment with imatinib (Gleevec) improves survival in patients with high-risk gastrointestinal stromal tumors (GIST). Imatinib administered for 3 ...

Patients with high-risk gastrointestinal stromal tumors (GISTs) had a 60% improvement in 3-year disease-free survival (DFS) with 6 versus 3 years of maintenance imatinib, a randomized trial showed.

Patients with advanced non-progressing gastrointestinal stromal tumors (GIST) who discontinued imatinib had more rapid progression, faster development of resistance, and worse overall survival (OS), a ...

Interim results of the randomized, phase 3 PhALLCON trial indicate ponatinib’s benefit over imatinib in frontline treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), ...

We report the case of a 16-year-old male who was initially diagnosed with Ph-positive ALL at the age of 14 years. He presented with poor prognostic factors, including a WBC count of 390 × 10 9 per L ...

The phase 3 PhALLCON study found ponatinib plus chemotherapy more effective than imatinib with chemotherapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. BCR-ABL1 ...

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference. The study investigated ...

We report the case of a nulliparous, 70-year-old woman with long-standing type 2 diabetes mellitus who had regression of the disease during treatment of chronic myeloid leukemia with imatinib, an ...

The Appraisal Committee considered evidence submitted by Novartis Pharmaceuticals and a review of this submission by the Evidence Review Group (ERG). ACOSOG Z9001 was a randomised, double‑blind, ...